Nature Search

SARS-CoV-2 evolution during treatment of chronic infection

Chronic infection with SARS-CoV-2 leads to the emergence of viral variants that show reduced susceptibility to neutralizing antibodies in an immunosuppressed individual treated with convalescent plasma.

Steven A. Kemp
Dami A. Collier
Ravindra K. Gupta
Research05 Feb 2021
Nature

Volume: 592, P: 277-282
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Sera from vaccinated individuals and some monoclonal antibodies show a modest reduction in neutralizing activity against the B.1.1.7 variant of SARS-CoV-2; but the E484K substitution leads to a considerable loss of neutralizing activity.

Dami A. Collier
Anna De Marco
Ravindra K. Gupta
Research11 Mar 2021
Nature

Volume: 593, P: 136-141
Thresholds for adding degraded tropical forest to the conservation estate

An analysis of the impact of logging intensity on biodiversity in tropical forests in Sabah, Malaysia, identifies a threshold of tree biomass removal below which logged forests still have conservation value.

Robert M. Ewers
C. David L. Orme
Cristina Banks-Leite
ResearchOpen Access17 Jul 2024
Nature

Volume: 631, P: 808-813
Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease

Openshaw and colleagues find myeloid inflammation and complement activation signatures in patients with long COVID who were previously hospitalized.

Felicity Liew
Claudia Efstathiou
J. Eunice Zhang
ResearchOpen Access08 Apr 2024
Nature Immunology

Volume: 25, P: 607-621
A systemic risk assessment methodological framework for the global polycrisis

This paper proposes a framework to assess systemic risks that compound and cascade within and between systems. This emphasizes political economy and transformations, as well as trans-disciplinarity and diverse participation, evidence and methods.

Ajay Gambhir
Michael J. Albert
Ruth Richardson
ReviewsOpen Access14 Aug 2025
Nature Communications

Volume: 16, P: 1-14
Author Correction: SARS-CoV-2 evolution during treatment of chronic infection

Steven A. Kemp
Dami A. Collier
Ravindra K. Gupta
Amendments and Corrections21 Jul 2022
Nature

Volume: 608, P: E23
Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases

In this immunological ancillary study of the PREVAC trial, the authors show that approved Ebola virus vaccines induce memory T-cell responses that persist during the five year follow-up after initial vaccination.

Aurélie Wiedemann
Edouard Lhomme
Huanying Zhou
ResearchOpen Access03 Sept 2024
Nature Communications

Volume: 15, P: 1-15
Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Dami A. Collier
Anna De Marco
Ravindra K. Gupta
Amendments and Corrections21 Jul 2022
Nature

Volume: 608, P: E24
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Vaccination is effective in protecting from COVID-19. Here the authors report immune responses and breakthrough infections in twice-vaccinated patients receiving anti-TNF treatments for inflammatory bowel disease, and find dampened vaccine responses that implicate the need of adapted vaccination schedules for these patients.

Simeng Lin
Nicholas A. Kennedy
Jeannie Bishop
ResearchOpen Access16 Mar 2022
Nature Communications

Volume: 13, P: 1-14
Better out than in

Continued US membership in the Paris Agreement on climate would be symbolic and have no effect on US emissions. Instead, it would reveal the weaknesses of the agreement, prevent new opportunities from emerging, and gift greater leverage to a recalcitrant administration.

Luke Kemp
Comments & Opinion22 May 2017
Nature Climate Change

Volume: 7, P: 458-460
Limiting the climate impact of the Trump administration

Luke Kemp
Comments & OpinionOpen Access31 Oct 2017
Palgrave Communications

Volume: 3, P: 1-5
AMPK phosphosite profiling by label-free mass spectrometry reveals a multitude of mTORC1-regulated substrates

William J. Smiles
Ashley J. Ovens
Jonathan S. Oakhill
ResearchOpen Access04 Mar 2025
npj Metabolic Health and Disease

Volume: 3, P: 1-22
Targeting protein aggregation for the treatment of degenerative diseases

The misfolding and aggregation of specific proteins — a process known as amyloidogenesis — seem to underlie a range of degenerative disorders. Here, Kelly and colleagues discuss the current understanding of the process and pathological role of protein aggregation, focusing on emerging disease-modifying strategies to ameliorate aggregation-associated degenerative disorders.

Yvonne S. Eisele
Cecilia Monteiro
Jeffery W. Kelly
Reviews04 Sept 2015
Nature Reviews Drug Discovery

Volume: 14, P: 759-780
Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo

Richard Spritz and colleagues report genome-wide association analyses identifying 13 new susceptibility loci for generalized vitiligo. Their functional pathway analysis shows that many vitiligo susceptibility loci encode immunoregulatory proteins or melanocyte components.

Ying Jin
Stanca A Birlea
Richard A Spritz
Research06 May 2012
Nature Genetics

Volume: 44, P: 676-680
Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants

Richard Spritz and colleagues present a genome-wide association study of autoimmune vitiligo in 4,680 cases and 39,586 controls and report 23 new risk loci. Their results highlight specific pathways, including immune response, apoptosis and melanocyte function, that may be important in the pathobiology of autoimmune vitiligo.

Ying Jin
Genevieve Andersen
Richard A Spritz
Research10 Oct 2016
Nature Genetics

Volume: 48, P: 1418-1424
Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression

D. Luke Fischer
Fredric P. Manfredsson
Caryl E. Sortwell
ResearchOpen Access27 Nov 2017
Scientific Reports

Volume: 7, P: 1-17
Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA

K W Douglas
A N Parker
J Treisman
Research28 Feb 2011
Bone Marrow Transplantation

Volume: 47, P: 18-23

Search

Filter By:

Search

Quick links